Latest News and Press Releases

Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients

PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...

CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN

Curium advances cancer care with its 505(b)(2) NDA submission to the FDA for Lutetium Lu 177 Dotatate Injection in GEP-NETS patients.

Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...

Curium partners with Institut Laue–Langevin to enhance Lutetium-177 supply, benefiting over 100,000 cancer patients in five years.

first doses of PYLCLARI in France for prostate cancer patients

PARIS, 30 mai 2024 (GLOBE NEWSWIRE) -- Curium, leader mondial de la médecine nucléaire, annonce aujourd'hui que suite à la Publication au Journal Officiel du 2 mai, , les patients français ont reçu...

PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for...